Duloxetine Found Ineffective in Preventing Chemotherapy-Induced Peripheral Neuropathy in Colorectal Cancer Patients

A recent clinical trial has determined that duloxetine, an antidepressant commonly used to treat painful neuropathy after its onset, does not prevent chemotherapy-induced peripheral neuropathy (CIPN) in patients undergoing treatment for colorectal cancer. The randomized study, conducted by the Alliance for Clinical Trials in Oncology and supported by the National Cancer Institute, aimed to evaluate whether the drug could serve as a preventive measure against this common side effect of chemotherapy.

The trial involved colorectal cancer patients receiving chemotherapy who were administered duloxetine to assess its effectiveness in preventing CIPN. Despite prior evidence supporting duloxetine’s use in managing existing neuropathic pain, the findings indicate that it does not provide protective benefits when used preemptively. Researchers conducted a rigorous evaluation process to reach these conclusions, highlighting the need for further studies to identify effective strategies for preventing CIPN in cancer patients.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: April 8, 2026

Author

GOAI